A 84538
1,3-Thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Ritonavir
A-84538
No
Abbott 84538
{SNA} Bioactive Small Molecule Alphabetical Index, R, 生物活性小分子, 细胞生物学
Anti-virals
Non-nucleoside Reverse Transcriptase
Intermediates & Fine Chemicals
{SNA} Analytical Standards, EP Standards, EP Standards P - R, Pharmacopeia & Metrological Institutes Standards, 分析/色谱
Inhibitors,
{SNA} Cell Biology, Cell Signaling and Neuroscience, Immune Cell Signaling,
产品应用
A selective HIV protease inhibitor.
相关文献及参考
[2]. Kumar GN, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277(1):423-31.
[3]. Weichold FF, et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2(5):261-9.
[4]. Drewe J, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999 May 15;57(10):1147-52.
[5]. Kumar GN, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug;27(8):902-8.
[6]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May
安全信息
Safety Statements
S36/37 Wear suitable protective clothing and gloves 穿戴适当的防护服和手套;
GHS Symbol
Precautionary statements
Hazard statements
H302+H312+H332
WGK Germany
3
Signal word
RTECS
XA5310000
Hazard Codes
Xn
Risk Statements
R20/21/22 Harmful by inhalation, in contact with skin and if swallowed 吸入、皮肤接触和不慎吞咽有害